Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 17/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237961 | 1.00 | MYB (0.80) | MYBKDM4EGAAMAPTRAB9A | |
| SCHEMBL8117263 | 0.87 | MYB (0.61) | MYBKDM4EMAPTRAB9A | |
| SCHEMBL8537195 | 0.86 | MYB (0.67) | MYBKDM4EGAAMAPTRAB9A | |
| SCHEMBL8543671 | 0.86 | MYB (1.00) | MYBMAPTRAB9A | |
| SCHEMBL31237908 | 0.85 | MYB (0.83) | MYBKDM4EGAAMAPTRAB9A | |
| SCHEMBL8808882 | 0.85 | MYB (0.58) | MYB | |
| SCHEMBL15614738 | 0.84 | MYB (1.00) | MYBMAPTRAB9A | |
| SCHEMBL4335346 | 0.84 | MYB (1.00) | MYB | |
| SCHEMBL4425533 | 0.84 | MAPK1 (0.57) | MYBKDM4EGAAMAPTRAB9A | |
| SCHEMBL8118633 | 0.83 | POLB (0.77) | MYBKDM4EGAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| EP-0537949-B1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY CO ELI (GB) | 1998-07-01 | — | — | EP | disclosed |
| EP-0618206-B1 | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5576325-A | TREATMENT OF IMMUNE DISEASES, RESTENOSIS, ENZYME INHIBITORS AND ANTISPASMODIC AGENTS | LILLY INDUSTRIES LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5574034-A | TREATMENT OF IMMUNE DISEASES AND EXCESS CELL PROLIFERATION, ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5571818-A | FOR TREATING IMMUNE DISEASES OR A DISEASE IN WHICH EXCESS CELL PROLIFERATION OR ENZYME RELEASE OCCUR | ELI LILLY AND COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514699-A | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| EP-0618206-A1 | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1994-10-05 | — | — | EP | disclosed |
| US-5284868-A | Naphthopyran derivatives; for autoimmune diseases, cancer | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0537949-A1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY INDUSTRIES LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | NFE2, NFE2L2, UBE2N | MYB 2214/4885KDM4E 4210/4885GAA 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.